

Thrombolytic Solutions for Peripheral Vascular Disease

Norman E. Lepor, MD, FACC, FAHA

Co-Editor, *Reviews in Cardiovascular Medicine*

Division of Cardiology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA

[Rev Cardiovasc Med. 2002;3(suppl 2):S1]

© 2002, 2003 MedReviews, LLC

We are proud to present this timely, objective, and comprehensive review of effective strategies to treat peripheral vascular thrombotic disorders. The recent return of urokinase (Abbokinase®, Abbott Laboratories, Abbott Park, IL) to the marketplace has created an opportunity to bring together the “best and brightest” thought leaders in the field of vascular medicine to create the content in this supplement, ***Thrombolytic Solutions for Peripheral Vascular Disease***.

Under the direction of Drs. Kenneth Ouriel and Barry Katzen, an assembly of vascular specialists, including Drs. Bell, Comerota, Connors, Cynamon, Deitcher, Jaff, Haskal, Meissner, and Olin, have made important contributions to this publication. This has allowed MedReviews to provide you with an objective evaluation of the role of thrombolytic therapy in the treatment of arterial and venous thrombotic disorders.

On a personal note, my own review of the contents of this supplement has clarified the important role of thrombolytic therapy (and urokinase in particular) in the treatment of pulmonary emboli, deep venous thrombosis, acute limb ischemia, thrombosed hemodialysis access grafts, and axillary-subclavian venous thrombosis. With the support of a grant from Abbott Laboratories, we have been afforded the opportunity to present an objective comparison of thrombolytic agents, mechanical thrombectomy devices and other percutaneous interventions, and surgery in the treatment of vascular thrombotic disorders and let the “chips fall where they may.”

When discussing thrombolytic therapy with my interventional radiology/cardiology and vascular surgery colleagues around the country, it is clear that urokinase is an agent that they have become most comfortable using. This seems to be the result of their own evaluations of available clinical data, coupled with their own anecdotal experiences.

I am certain that this supplement will provide important information that will have practical implications for patient care for years to come. Please feel free to provide feedback on this publication to us through the web site, www.medreviews.com. The biggest compliment you can give us is that we played a role in enhancing the care of your patients. ■